Merck KGaA

📅 Upcoming

🕒 Recent(90d)

News

• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
  A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.
  stat · 4d ago
• FDA starts review of Roche’s multiple sclerosis pill
  The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
  biopharma_dive · 4d ago
• Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
  Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including mul…
  biospace · 12d ago
• BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
  Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.
  biospace · 17d ago
• Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
  Pfizer and Merck KGaA's venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields. TwoStep Therapeutics collected…
  endpoints · 26d ago
• Beeline flies into phase 3 as oral lupus drug soars past placebo
  A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
  fiercebiotech · 26d ago
• Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
  Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and nec…
  fiercebiotech · 27d ago
• A year on from Big Pharma’s pull-back from the UK, has anything changed?
  September 2025 marked a low point for relations between the U.K. government and Big Pharma. Fierce reached out to the companies involved to see if they've softened their stance.
  fiercebiotech · 1mo ago
• Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
  Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and has raised $150 million, positioning the biotech to…
  fiercebiotech · 1mo ago